Milagros Flores
@dramiliflores.bsky.social
Nephron lover | #NephEdC #NephJC #ISNSoMe team #ISNWCN #SLANHJoven
#nefroneando avanzamos #butfirstcoffee ☕
Life traveler 🧳 🇭🇳🇲🇽🏳️🌈 🇬🇹🇸🇻🇺🇸🇪🇸🏴🇵🇹🇹🇷🇹🇭🇦🇷🇮🇹🇻🇦🇫🇷💥
#nefroneando avanzamos #butfirstcoffee ☕
Life traveler 🧳 🇭🇳🇲🇽🏳️🌈 🇬🇹🇸🇻🇺🇸🇪🇸🏴🇵🇹🇹🇷🇹🇭🇦🇷🇮🇹🇻🇦🇫🇷💥
We did a lot of sensitivity analyses (see Supplement) using various methods of recurrent event analysis that showed consistent results. Didn't matter how you sliced the fish!
December 3, 2025 at 2:40 AM
Reposted by Milagros Flores
Although, you admired the very beautiful visual abstract made by @brianrifkin.bsky.social, #NephJC team (ha, @nephroseeker.medsky.social ) loved fish oil so much that made another one, right after #KidneyWk simultaneous publication 🎣
www.nephjc.com/news/...
www.nephjc.com/news/...
December 3, 2025 at 2:04 AM
Although, you admired the very beautiful visual abstract made by @brianrifkin.bsky.social, #NephJC team (ha, @nephroseeker.medsky.social ) loved fish oil so much that made another one, right after #KidneyWk simultaneous publication 🎣
www.nephjc.com/news/...
www.nephjc.com/news/...
9/10
I want more info: Check out #NephJC summary by @notjustdialysis.bsky.social
✅ www.nephjc.com/news/...
Visual abstracts by @salinesolut.bsky.social
✅
I want more info: Check out #NephJC summary by @notjustdialysis.bsky.social
✅ www.nephjc.com/news/...
Visual abstracts by @salinesolut.bsky.social
✅
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an
APRIL/BAFF inhibitor for use in IgAN.
www.nephjc.com
November 20, 2025 at 4:20 AM
November 20, 2025 at 4:20 AM
5/10
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
November 20, 2025 at 4:17 AM
Reposted by Milagros Flores
T4a: #NephJC
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
KDIGO IgA Guidelines: A Patient Voice — NephJC
We have a patient perspective on the new IgA Guidelines and what it means
to live with IgA in these times.
www.nephjc.com
November 19, 2025 at 2:52 AM
T4a: #NephJC
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
Reposted by Milagros Flores
T3o: #NephJC
Although this is an exciting time with the FDA approving new therapies for IgAN rapidly - they are mostly not available or accessible outside a few select countries -especially in places like Asia where the bulk of IgAN patients live.
Implementation and equity have entered the chat.
Although this is an exciting time with the FDA approving new therapies for IgAN rapidly - they are mostly not available or accessible outside a few select countries -especially in places like Asia where the bulk of IgAN patients live.
Implementation and equity have entered the chat.
November 19, 2025 at 2:50 AM
T3o: #NephJC
Although this is an exciting time with the FDA approving new therapies for IgAN rapidly - they are mostly not available or accessible outside a few select countries -especially in places like Asia where the bulk of IgAN patients live.
Implementation and equity have entered the chat.
Although this is an exciting time with the FDA approving new therapies for IgAN rapidly - they are mostly not available or accessible outside a few select countries -especially in places like Asia where the bulk of IgAN patients live.
Implementation and equity have entered the chat.
Reposted by Milagros Flores
T3j: #NephJC
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
November 19, 2025 at 2:45 AM
T3j: #NephJC
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
Overall, these interim results suggest that APRIL-based and BAFF/APRIL–based therapies may represent important future disease-modifying options in IgAN
A full throated, “Hallelujah” being reserved until eGFR data is finalized.
Reposted by Milagros Flores
Stopping the source of disease seems much more productive that just treating the peripheral damage #NephJC
a man wearing glasses is making a funny face and saying that 's a lot of damage
ALT: a man wearing glasses is making a funny face and saying that 's a lot of damage
media.tenor.com
November 19, 2025 at 2:41 AM
Stopping the source of disease seems much more productive that just treating the peripheral damage #NephJC
Reposted by Milagros Flores
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
November 19, 2025 at 2:41 AM
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Reposted by Milagros Flores
T3e: #NephJC
As newer trials such as APPLAUSE-IgAN (iptacopan) & NEFIGARD (budesonide) continue to illuminate parts of the cascade, the APRIL–BAFF pathway stands out as the most direct attempt to target the source of pathogenic IgA production.
Will this class of meds become foundational in IgAN?
As newer trials such as APPLAUSE-IgAN (iptacopan) & NEFIGARD (budesonide) continue to illuminate parts of the cascade, the APRIL–BAFF pathway stands out as the most direct attempt to target the source of pathogenic IgA production.
Will this class of meds become foundational in IgAN?
November 19, 2025 at 2:40 AM
T3e: #NephJC
As newer trials such as APPLAUSE-IgAN (iptacopan) & NEFIGARD (budesonide) continue to illuminate parts of the cascade, the APRIL–BAFF pathway stands out as the most direct attempt to target the source of pathogenic IgA production.
Will this class of meds become foundational in IgAN?
As newer trials such as APPLAUSE-IgAN (iptacopan) & NEFIGARD (budesonide) continue to illuminate parts of the cascade, the APRIL–BAFF pathway stands out as the most direct attempt to target the source of pathogenic IgA production.
Will this class of meds become foundational in IgAN?
Reposted by Milagros Flores
Ongoing late posts from @theisn.org #ISNWCN
from the high impact trial session - this was a great study design
The India ALLIANCE GRACE IgAN trial
Lead by Succeena Alexander from CMC Vellore
#NephSky
1/
from the high impact trial session - this was a great study design
The India ALLIANCE GRACE IgAN trial
Lead by Succeena Alexander from CMC Vellore
#NephSky
1/
November 19, 2025 at 2:39 AM
Reposted by Milagros Flores
T3d: #NephJC
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
November 19, 2025 at 2:39 AM
T3d: #NephJC
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
In VISIONARY, APRIL-selective B-cell inhibition ⬇️proteinuria & IgA-related biomarkers, confirming APRIL’s key pathogenic role.
In ORIGIN-3, atacicept’s BAFF + APRIL blockade targets earlier B-cell checkpoints, dismantling both the production & maintenance of aberrant IgA response.
Reposted by Milagros Flores
T3c: #NephJC
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
November 19, 2025 at 2:38 AM
T3c: #NephJC
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
Reposted by Milagros Flores
Reposted by Milagros Flores
T3b: #NephJC
This interim analysis produced clear improvements in key biomarkers of IgAN.
The magnitude of the proteinuria reduction & parallel drop in Gd-IgA1 support the idea that atacicept is acting directly on the drivers of disease, rather than through non-specific hemodynamic effects.
This interim analysis produced clear improvements in key biomarkers of IgAN.
The magnitude of the proteinuria reduction & parallel drop in Gd-IgA1 support the idea that atacicept is acting directly on the drivers of disease, rather than through non-specific hemodynamic effects.
November 19, 2025 at 2:37 AM
T3b: #NephJC
This interim analysis produced clear improvements in key biomarkers of IgAN.
The magnitude of the proteinuria reduction & parallel drop in Gd-IgA1 support the idea that atacicept is acting directly on the drivers of disease, rather than through non-specific hemodynamic effects.
This interim analysis produced clear improvements in key biomarkers of IgAN.
The magnitude of the proteinuria reduction & parallel drop in Gd-IgA1 support the idea that atacicept is acting directly on the drivers of disease, rather than through non-specific hemodynamic effects.
Reposted by Milagros Flores
Not sure Gd-IgA is meaningful beyond an association
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
We need a good biomarker for IgAN given the impoartance of immunosuppression (vs non-specific therapies: RASi, Flozins, ERA)
But the Gd-IgA doesn’t seem so impressive to me?
journals.lww.com/cjasn/pages/...
#NephSky @asnpublications.bsky.social #CJASN
VA by @corinateodosiu.bsky.social
But the Gd-IgA doesn’t seem so impressive to me?
journals.lww.com/cjasn/pages/...
#NephSky @asnpublications.bsky.social #CJASN
VA by @corinateodosiu.bsky.social
November 19, 2025 at 2:37 AM
Not sure Gd-IgA is meaningful beyond an association
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
Reposted by Milagros Flores
T2e: #NephJC
2° Endpoints
📉Atacicept reduced Gd-IgA1 by 68.3% at week 36 vs 2.9% with placebo, as early as week 4
🩸Among patients with baseline ≥1+ hematuria, 81% in the atacicept group achieved resolution vs 21% with placebo arm
🥤UACR ratio fell by 47.3% in atacicept vs 8.8% with placebo
2° Endpoints
📉Atacicept reduced Gd-IgA1 by 68.3% at week 36 vs 2.9% with placebo, as early as week 4
🩸Among patients with baseline ≥1+ hematuria, 81% in the atacicept group achieved resolution vs 21% with placebo arm
🥤UACR ratio fell by 47.3% in atacicept vs 8.8% with placebo
November 19, 2025 at 2:33 AM
T2e: #NephJC
2° Endpoints
📉Atacicept reduced Gd-IgA1 by 68.3% at week 36 vs 2.9% with placebo, as early as week 4
🩸Among patients with baseline ≥1+ hematuria, 81% in the atacicept group achieved resolution vs 21% with placebo arm
🥤UACR ratio fell by 47.3% in atacicept vs 8.8% with placebo
2° Endpoints
📉Atacicept reduced Gd-IgA1 by 68.3% at week 36 vs 2.9% with placebo, as early as week 4
🩸Among patients with baseline ≥1+ hematuria, 81% in the atacicept group achieved resolution vs 21% with placebo arm
🥤UACR ratio fell by 47.3% in atacicept vs 8.8% with placebo
Reposted by Milagros Flores
T2d: #NephJC
📉The decline in proteinuria was already evident by week 12 & continued thru week 36
🚨Prespecified subgroup analyses showed that this benefit was consistent across all categories, including age, sex, region, race, baseline UPCR/ eGFR & SGLT2i use
📉The decline in proteinuria was already evident by week 12 & continued thru week 36
🚨Prespecified subgroup analyses showed that this benefit was consistent across all categories, including age, sex, region, race, baseline UPCR/ eGFR & SGLT2i use
November 19, 2025 at 2:32 AM
T2d: #NephJC
📉The decline in proteinuria was already evident by week 12 & continued thru week 36
🚨Prespecified subgroup analyses showed that this benefit was consistent across all categories, including age, sex, region, race, baseline UPCR/ eGFR & SGLT2i use
📉The decline in proteinuria was already evident by week 12 & continued thru week 36
🚨Prespecified subgroup analyses showed that this benefit was consistent across all categories, including age, sex, region, race, baseline UPCR/ eGFR & SGLT2i use
Reposted by Milagros Flores
T2c: #NephJC
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
November 19, 2025 at 2:31 AM
T2c: #NephJC
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
1° Endpoint
At week 36- 🗓️
📉Atacicept: 24-hour urinary protein-to-creatinine ratio decreased by 45.7%
🔻Placebo: 24-hour urinary protein-to-creatinine ratio decreased by 6.8%
Reposted by Milagros Flores
T2b: #NephJC
99.5% of patients were already receiving the max tolerated dose of a RASi at baseline, & just over half (53.2%) were #flozinated
About 60% had 1+ or more hematuria, with proteinuria 2 g/day & preserved GFR (60 ml/min).
Are these the patients you most often encounter with IgAN?
99.5% of patients were already receiving the max tolerated dose of a RASi at baseline, & just over half (53.2%) were #flozinated
About 60% had 1+ or more hematuria, with proteinuria 2 g/day & preserved GFR (60 ml/min).
Are these the patients you most often encounter with IgAN?
November 19, 2025 at 2:30 AM
T2b: #NephJC
99.5% of patients were already receiving the max tolerated dose of a RASi at baseline, & just over half (53.2%) were #flozinated
About 60% had 1+ or more hematuria, with proteinuria 2 g/day & preserved GFR (60 ml/min).
Are these the patients you most often encounter with IgAN?
99.5% of patients were already receiving the max tolerated dose of a RASi at baseline, & just over half (53.2%) were #flozinated
About 60% had 1+ or more hematuria, with proteinuria 2 g/day & preserved GFR (60 ml/min).
Are these the patients you most often encounter with IgAN?
Reposted by Milagros Flores
T2a: #NephJC
A total of 203 participants were included in the 36-week interim efficacy analysis, with 106 patients receiving atacicept and 97 patients receiving placebo.
A total of 203 participants were included in the 36-week interim efficacy analysis, with 106 patients receiving atacicept and 97 patients receiving placebo.
November 19, 2025 at 2:29 AM
T2a: #NephJC
A total of 203 participants were included in the 36-week interim efficacy analysis, with 106 patients receiving atacicept and 97 patients receiving placebo.
A total of 203 participants were included in the 36-week interim efficacy analysis, with 106 patients receiving atacicept and 97 patients receiving placebo.